By Regulatory Approvals — FDA Approves Brepocitinib as First Oral Drug for Dermatomyositis The American Journal of Managed Care
Read the original at Regulatory Approvals ↗
Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. August 28, 2026.